Breaking News Instant updates and real-time market news.

NSRGY

Nestle

$0.00

(0.00%)

, NVS

Novartis

$92.37

-0.41 (-0.44%)

16:33
06/25/19
06/25
16:33
06/25/19
16:33

Nestle, Novartis among multinationals at risk of London trading ban, WSJ says

Trading in Switzerland's largest companies, including Nestle (NSRGY) and Novartis (NVS), could be banned in London and other major financial centers as a political spat with the European Union threatens to affect markets, Brian Blackstone and Avantika Chilkoti of the Wall Street Journal report. Switzerland and the EU are in conflict over a revamp of the complex ties that have guided the relationship between the two parties for decades, Blackstone and Chilkoti say. If an EU-imposed deadline passed on Sunday without a deal, venues on the EU would be limited in trading Swiss stocks, meaning that the ability of some investors to trade blue-chip Swiss companies could be affected, the authors note. Switzerland is not a member of the EU, though it has extensive financial, immigration, and trade ties with the bloc, the authors note. Reference Link

NSRGY

Nestle

$0.00

(0.00%)

NVS

Novartis

$92.37

-0.41 (-0.44%)

  • 25

    Sep

NSRGY Nestle
$0.00

(0.00%)

01/24/19
BREN
01/24/19
UPGRADE
BREN
Buy
Nestle upgraded to Buy from Hold at Berenberg
Berenberg analyst James Targett upgraded Nestle to Buy after his analysis showed large brands outperform, particularly in home care, hygiene and parts of personal care and packaged food. The analyst finds shares of Nestle as attractive.
01/29/19
SOCG
01/29/19
INITIATION
SOCG
Buy
Nestle initiated with a Buy at Societe Generale
Societe Generale started Nestle with a Buy rating and CHF95 price target
02/19/19
RBCM
02/19/19
DOWNGRADE
RBCM
Sector Perform
Nestle downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst James Jones downgraded Nestle to Sector Perform saying expectations for improved sales growth is priced into the shares following the recent rally.
04/10/19
LEHM
04/10/19
INITIATION
LEHM
Overweight
Nestle initiated with an Overweight at Barclays
Barclays analyst Warren Ackerman yesterday afternoon initiated coverage of Nestle with an Overweight rating and price target of 106 francs. The analyst sees potential for the company to unlock value despite the recent rally in the shares.
NVS Novartis
$92.37

-0.41 (-0.44%)

05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.
06/03/19
06/03/19
DOWNGRADE

Perform
Aduro Biotech downgraded to Perform on lack of catalysts at Oppenheimer
As previously reported, Oppenheimer analyst Mark Breidenbach downgraded Aduro Biotech (ADRO) to Perform from Outperform given the company's lack of near-term catalysts. The analyst notes that Aduro's partner Novartis (NVS) presented initial clinical results from an ongoing Phase 1b trial of ADU-S100 in combination with spartalizumab in advanced tumors at ASCO. Given the pretreatment history of these patients, he cannot state with confidence that the responses observed were dependent on ADUS100, and the trial data suggests dosing has not yet been fully optimized. As Novartis continues to evaluate the STING agonist, Breidenbach anticipates an extended development timeline.
06/14/19
PIPR
06/14/19
NO CHANGE
Target $120
PIPR
Neutral
Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray
The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.
06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.

TODAY'S FREE FLY STORIES

GNTX

Gentex

$23.54

0.01 (0.04%)

08:05
07/19/19
07/19
08:05
07/19/19
08:05
Earnings
Gentex narrows FY19 revenue guidance $1.87B-$1.9B from $1.83B-$1.93B 

Consensus $1.87B.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

CMG

Chipotle

$764.23

11.92 (1.58%)

08:03
07/19/19
07/19
08:03
07/19/19
08:03
Initiation
Chipotle initiated  »

Chipotle reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

GNTX

Gentex

$23.54

0.01 (0.04%)

08:03
07/19/19
07/19
08:03
07/19/19
08:03
Earnings
Gentex reports Q2 EPS 42c, consensus 40c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

HQY

HealthEquity

$76.39

0.96 (1.27%)

, WAGE

WageWorks

$50.79

-0.01 (-0.02%)

08:02
07/19/19
07/19
08:02
07/19/19
08:02
Recommendations
HealthEquity, WageWorks analyst commentary  »

HealthEquity price target…

HQY

HealthEquity

$76.39

0.96 (1.27%)

WAGE

WageWorks

$50.79

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$36.09

0.54 (1.52%)

, PYPL

PayPal

$119.87

1.07 (0.90%)

08:00
07/19/19
07/19
08:00
07/19/19
08:00
Hot Stocks
Synchrony says average active accounts were up 9% in Q2 »

Synchrony (SYF) says it…

SYF

Synchrony

$36.09

0.54 (1.52%)

PYPL

PayPal

$119.87

1.07 (0.90%)

WMT

Walmart

$114.68

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 24

    Jul

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

NFLX

Netflix

$325.14

-37.36 (-10.31%)

08:00
07/19/19
07/19
08:00
07/19/19
08:00
Options
Netflix call buyer realizes 3% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

SKX

Skechers

$34.75

0.35 (1.02%)

07:59
07/19/19
07/19
07:59
07/19/19
07:59
Recommendations
Skechers analyst commentary  »

Skechers price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$56.27

1.67 (3.06%)

07:55
07/19/19
07/19
07:55
07/19/19
07:55
Hot Stocks
State Street boosts productivity savings for FY19 to 4.5% from 4% »

State Street says it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

WNS

WNS Holdings

$62.34

3.8 (6.49%)

07:53
07/19/19
07/19
07:53
07/19/19
07:53
Recommendations
WNS Holdings analyst commentary  »

WNS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

MSFT

Microsoft

$136.29

0.06 (0.04%)

07:52
07/19/19
07/19
07:52
07/19/19
07:52
Recommendations
Microsoft analyst commentary  »

Microsoft still has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

07:51
07/19/19
07/19
07:51
07/19/19
07:51
Recommendations
Crowdstrike analyst commentary  »

Crowdstrike price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WW

WW

$25.18

1.23 (5.14%)

07:49
07/19/19
07/19
07:49
07/19/19
07:49
Upgrade
WW rating change  »

WW upgraded to Buy at DA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

07:49
07/19/19
07/19
07:49
07/19/19
07:49
Recommendations
Microsoft analyst commentary  »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

DOW

Dow Inc.

$51.76

0.15 (0.29%)

07:48
07/19/19
07/19
07:48
07/19/19
07:48
Initiation
Dow Inc. initiated  »

Dow Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 24

    Sep

NGVT

Ingevity

07:44
07/19/19
07/19
07:44
07/19/19
07:44
Downgrade
Ingevity rating change  »

Jefferies downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

INDB

Independent Bank

$73.31

0.56 (0.77%)

07:44
07/19/19
07/19
07:44
07/19/19
07:44
Upgrade
Independent Bank rating change  »

Independent Bank upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

KBR

KBR

$25.28

0.36 (1.44%)

07:43
07/19/19
07/19
07:43
07/19/19
07:43
Upgrade
KBR rating change  »

KBR upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

MDR

McDermott

$10.20

-0.25 (-2.39%)

07:41
07/19/19
07/19
07:41
07/19/19
07:41
Hot Stocks
McDermott awarded pre-FEED contract by YPF in Argentina »

McDermott has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

ADTN

Adtran

$12.12

-3.72 (-23.48%)

, DTE

DTE Energy

$131.39

1.27 (0.98%)

07:41
07/19/19
07/19
07:41
07/19/19
07:41
Recommendations
Adtran, DTE Energy analyst commentary at MKM Partners »

Adtran price target…

ADTN

Adtran

$12.12

-3.72 (-23.48%)

DTE

DTE Energy

$131.39

1.27 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 02

    Oct

AXS

Axis Capital

, ACGL

Arch Capital

$38.24

0.12 (0.31%)

07:41
07/19/19
07/19
07:41
07/19/19
07:41
Recommendations
Axis Capital, Arch Capital, Travelers, Hartford Financial analyst commentary at Buckingham »

Buckingham upgrades Axis…

AXS

Axis Capital

ACGL

Arch Capital

$38.24

0.12 (0.31%)

TRV

Travelers

$152.69

0.27 (0.18%)

HIG

Hartford Financial

$57.90

0.24 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 30

    Jul

  • 31

    Jul

  • 02

    Aug

  • 06

    Aug

07:40
07/19/19
07/19
07:40
07/19/19
07:40
General news
Treasury Market Outlook: Treasuries are a little weaker »

Treasury Market Outlook:…

WNS

WNS Holdings

$62.34

3.8 (6.49%)

07:39
07/19/19
07/19
07:39
07/19/19
07:39
Recommendations
WNS Holdings analyst commentary  »

WNS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

07:38
07/19/19
07/19
07:38
07/19/19
07:38
Recommendations
Intuitive Surgical analyst commentary at Canaccord »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 09

    Sep

AXP

American Express

$128.40

1.355 (1.07%)

07:37
07/19/19
07/19
07:37
07/19/19
07:37
Earnings
American Express backs FY19 adj. EPS view of $7.85-$8.35, consensus $8.13 »

Backs FY19 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 13

    Nov

EXPO

Exponent

$61.63

0.83 (1.37%)

07:37
07/19/19
07/19
07:37
07/19/19
07:37
Recommendations
Exponent analyst commentary  »

Exponent price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.